Biotechnology · Waltham, Massachusetts, United States
$22.64
+0.47% (+$0.11)2026-07-09
Smart-Money SignalNeutral · 51/100— Insider open-market flow is flat over 90 days
Net Income-$40.4M
EPS$-0.57
Market Cap$1.1B
Price Performance
Historical data including institutional events
Company Profile
T
Tom Frohlich
CEO & Executive Director
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.
The compnay also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
